Purpose of Review

Sickle cell disease (SCD) remains among the most common and severe monogenic disorders present in the world today. Although sickle cell pain has been traditionally characterized as nociceptive, a significant portion of sickle cell patients has reported neuropathic pain symptoms. Our review article will discuss clinical aspects of SCD-related neuropathic pain, epidemiology of neuropathic pain among individuals with SCD, pain mechanisms, and current and future potential pharmacological interventions.

Recent Findings

Neuropathic pain in SCD is a complicated condition that often has a lifelong and significant negative impact on life; therefore, improved pain management is considered a significant and unmet need. Neuropathic pain mechanisms are heterogeneous, and the difficulty in determining their individual contribution to specific pain types may contribute to poor treatment outcomes in this population.

Summary

Our review article outlines several pharmacological modalities which may be employed to treat neuropathic pain in SCD patients.

中文翻译：

---

神经性疼痛和镰状细胞病：药理管理的回顾。

审查目的

镰状细胞病（SCD）仍然是当今世界上最常见和最严重的单基因疾病之一。尽管镰状细胞疼痛传统上被表征为伤害性疼痛，但仍有相当一部分镰状细胞患者报告了神经性疼痛症状。我们的综述文章将讨论与SCD相关的神经性疼痛的临床方面，患有SCD的个体中神经性疼痛的流行病学，疼痛机制以及当前和未来的潜在药理干预措施。

最近的发现

SCD中的神经性疼痛是一种复杂的疾病，通常会终生并且对生命产生重大的负面影响。因此，改善疼痛管理被认为是重要且未得到满足的需求。神经性疼痛机制是多种多样的，难以确定其对特定疼痛类型的个体贡献可能会导致该人群的治疗效果差。

概要

我们的综述文章概述了可用于治疗SCD患者神经性疼痛的几种药理方法。